OncoMatch/Clinical Trials/NCT02728388
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
Is NCT02728388 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies aminolevulinic acid for neurofibromatosis 1.
Treatment: aminolevulinic acid — The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: chemotherapy
Previous chemotherapy within 6 weeks of proposed PDT
Cannot have received: tumor therapy
Other concurrent tumor therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Donald G Basel · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify